Epidemiology and Outcomes of Neonatal Hemophagocytic Lymphohistiocytosis.
HLH
hemophagocytic lymphohistiocytosis
multi organ dysfunction
neonatal
sepsis
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
01
2022
accepted:
07
03
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
Neonatal hemophagocytic lymphohistiocytosis (HLH) is a rare entity. The objective of the study was to describe the prevalence, clinical characteristics, interventions and outcomes of neonates diagnosed with HLH in the United States. A retrospective analysis of 2009, 2012, and 2016 Kids' Inpatient Database was performed. Neonates discharged/died with a diagnosis of HLH were identified and analyzed. Among 11,130,055 discharges, 76 neonates had a diagnosis of HLH. Fifty-two percent (95% CI: 38.6-63.6) were males and 54% (95% CI: 39.7-68.5) were white. Herpes simplex infection was present in 16% (95% CI: 9.2-28.1). 24.4% (95% CI: 14.5-37.9) received chemotherapy, 11.5% (95% CI: 5.2-23.6) IVIG and 3.6% (95% CI: 0.8-14.4) allogenic hemopoietic stem cell transplantation. Organ dysfunction was commonly seen and severe sepsis was documented in 26.6% (95% CI: 16.4-39.9). Median LOS was 16 (IQR 7-54) days. The mortality was 42% (95% CI: 30.8-55). HLH is a rare diagnosis and carries a high mortality in neonates. Herpes simplex virus is the most common infection associated with neonatal HLH. HLH should be considered in the differential diagnosis in neonates presenting with multi-organ dysfunction or sepsis.
Identifiants
pubmed: 35558361
doi: 10.3389/fped.2022.848004
pmc: PMC9090447
doi:
Types de publication
Journal Article
Langues
eng
Pagination
848004Informations de copyright
Copyright © 2022 Balakumar, Sendi and Totapally.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Med Genet. 2009 Nov-Dec;52(6):417-20
pubmed: 19595804
Neoreviews. 2019 Jun;20(6):e316-e325
pubmed: 31261095
Pediatr Blood Cancer. 2007 Feb;48(2):124-31
pubmed: 16937360
Clin Nucl Med. 2021 Jul 1;46(7):595-598
pubmed: 33512953
Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S82-9
pubmed: 19932759
Pediatr Blood Cancer. 2018 Nov;65(11):e27344
pubmed: 30070073
Am J Perinatol. 2011 May;28(5):337-46
pubmed: 21089006
J Pediatr Hematol Oncol. 2008 Dec;30(12):871-6
pubmed: 19131769
Tohoku J Exp Med. 2019;247(3):149-152
pubmed: 30828029
Leukemia. 1996 Feb;10(2):197-203
pubmed: 8637226
Clin Nucl Med. 2021 Nov 1;46(11):935-937
pubmed: 34034321
Diagn Interv Radiol. 2016 Sep-Oct;22(5):471-5
pubmed: 27537853
Infection. 2017 Jun;45(3):355-359
pubmed: 28093696
J Perinatol. 2004 Jul;24(7):458-60
pubmed: 15224121
Blood. 2002 Oct 1;100(7):2367-73
pubmed: 12239144
Arab J Gastroenterol. 2016 Jun;17(2):105-9
pubmed: 27397412
Pediatrics. 2018 Apr;141(Suppl 5):S475-S480
pubmed: 29610175
Eur J Pediatr. 2007 Feb;166(2):95-109
pubmed: 17151879
Pediatr Blood Cancer. 2019 Nov;66(11):e27929
pubmed: 31339233
Eur J Pediatr. 2005 May;164(5):315-9
pubmed: 15731905
J Pediatr. 2009 Aug;155(2):235-8.e1
pubmed: 19446847